Yearly vs every-6-month infusions for active MS
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study compares receiving ocrelizumab infusions every 6 months versus once a year for people with active MS who have already been on treatment for 2 years. The goal is to see if yearly infusions work just as well to keep the disease quiet on MRI scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You are currently receiving ocrelizumab (Ocrevus) and have had at least 4 infusions (about 2 years of treatment)
- You have had no MS relapses in the last 18 months
- You have an EDSS score between 0 and 6 (you can walk without aid or with some help)
- You are able to have an MRI with contrast
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with relapsing multiple sclerosis who are switching from ocrelizumab to ofatumumab (two similar MS medications) to see how their immune system proteins (immunoglobulins) change during the switch. It may help doctors understand if this change improves your immune health while treating MS.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
This study looks at giving ocrelizumab treatments at home instead of in a clinic for people with MS. It’s meant to see if this approach is practical and acceptable while you keep receiving a medicine your MS doctor thinks you should continue.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.